Market Overview

UPDATE: Canaccord Genuity Lowers PT to $97 on Laboratory Corporation of America Holdings

Related LH
LabCorp Announces The Availability Of InformaSeqSM Non-Invasive Prenatal Test
Earnings Scheduled For July 18, 2014

Canaccord Genuity reiterated its Buy rating on Laboratory Corporation of America Holdings (NYSE: LH) and reduced its price target from $100 to $97.

Canaccord Genuity noted, "Although pressures remain, we reiterate our BUY rating as we think LH is the best-of-breed, low-cost lab provider with strong cash flow. We believe LH is growing faster than its competitors, and our survey checks suggest LH should benefit from an uptick in lab utilization next year. … We lower our price target to $97 (from $100), and assume that LH trades at ~13x our revised 2013 adj. EPS estimate of $7.43 (previously $7.50). LH has historically traded at ~14x EPS."

Laboratory Corporation of America Holdings closed at $90.21 on Wednesday.

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (LH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters